Some 65% of US employers agree that rising drug prices will force healthplan sponsors to shift from a co-payment to a percentage-based co-insurance structure, a recent survey commissioned by the International Society of Certified Employee Benefit Specialists has found. The survey, of a sample of the Society's 3,700 US members, also found that 78% of respondents now use a co-payment structure of cost-sharing, indicating that a significant shift of many benefit structures is around the corner.
The study found that 37% of employers have already made efforts to control their costs by raising the amount of employee co-payment or co-insurance. About 31% are considering cost-sharing increases, while another 32% are thinking about implementing a formulary or altering the formulary they currently use.
It also revealed that many employers are considering the possibility of limiting coverage of lifestyle drugs like Pfizer's impotence treatment Viagra (sildenafil).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze